...
首页> 外文期刊>The Pediatric infectious disease journal >Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection
【24h】

Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection

机译:双sofosbuvir / daclatasvir治疗对青少年乙型肝炎病毒感染的重量和线性生长的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12-17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.5%). Unlike interferon-based therapy, we did not detect significant negative effects on linear growth or weight. Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, .
机译:在治疗干扰素治疗慢性病毒性肝炎的儿童中报道了对生长指标的负面影响。 12至17岁的四十慢性丙型肝炎病毒感染的青少年接受Sofosbuvir / daclatasvir治疗治疗12周。 治疗结束后12周的意图治疗持续的病毒学反应率为39/40(97.5%)。 与基于干扰素的疗法不同,我们没有检测线性生长或重量的显着负面影响。 相反,观察到胃口和微不足道的重量增长的趋势,但需要进一步提高研究来确认。 见视频摘要,。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号